An interventional study of PRG-1801 (CAR-T against BCMA) in Lupus Nephritis and ANCA Associated Vasculitis, sponsored by Lingli Dong. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-02-26.
Sponsored by Lingli Dong · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 96 studies in Lupus Nephritis with a site in China — 43 open to participants now, 46 under way, 8 of them phase 3. Lupus Nephritis · China.
Among the 96 studies in Lupus Nephritis with a site in China, this one is the 59th largest by planned enrollment of the 88 interventional ones that give a count, is one of 6 that started in 2024, is one of 16 with no phase, reaches primary completion later than 9 of the 45 other live ones, and was the 58th registered.
343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.
Browse Lupus Nephritis studies →43 of the 96 studies in Lupus Nephritis with a site in China are open now. Recruiting first, the newest first:
Peking Union Medical College Hospital · Sites in China
Ages 6–18
Beijing GoBroad Hospital · Sites in China
Ages 6–65
Beijing Biotech · Sites in China
Ages 18–70
Nanjing University School of Medicine · Sites in China
Ages 14–65
China Immunotech (Beijing) Biotechnology Co., Ltd. · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
96 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 31 · Phase 3 22 · Phase 4 7
First in 1996; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 48 across 243 interventional studies indexed under Lupus Nephritis.
Median enrollment 51 across the 88 interventional studies, 400 across the 7 observational. Of the 34 that completed or were terminated, 11 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 96 have an industry lead sponsor. The 10 most frequent:
Lingli Dong is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Lingli Dong has 1 study filed under Lupus Nephritis — fewer than ten, so there is no comparison to draw.
17 of the studies in Lupus Nephritis with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT06406205Phase 3Qilu Pharmaceutical Co., Ltd.A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis | 2027-06 |
| NCT05126277Phase 3Novartis PharmaceuticalsSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | 2027-09-21 |
| NCT07236762China Immunotech (Beijing) Biotechnology Co., Ltd.An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases | 2026-11-24 |
| NCT07706998Nanjing UniversityApplication of the AI Platform iLN Based on DeepSeek in the Teaching of Lupus Nephritis | 2026-12-31 |
Add all 17 to your calendar (.ics) → With an account.
Among the 96 studies in Lupus Nephritis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Lupus nephritis (LN) and ANCA-associated vasculitis are severe autoimmune diseases, which may lead to the death of patients, particularly when they are refractory to the conventional therapeutic agents. Based on the current knowledge, the autoantibodies against self-antigens may exert important pathological roles in the pathogenesis of both LN and ANCA-associated vasculitis, of which the origins are primarily plasmablasts and plasma cells. BCMA is the molecule expressed on memory B cells, plasmablasts and plasma cells, and therefore is an ideal target for the elimination of potential pathogenic antibody secreting cells. Chimeric antigen receptor (CAR) T cells against BCMA may provide a novel therapeutic way for the refractory LN and ANCA-associated vasculitis patients to eliminate the pathogenic autoantibody-secreting cells. In this study, the safety and efficacy of a novel CAR-T cell therapy using PRG-1801 cells, are evaluated in patients with refractory LN and ANCA-associated vasculitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The following test values within 3 days before the collection of mononuclear cells meet the following standards:
for ANCA-associated vasculitis
①According to the 2022ACR/EULAR criteria, diagnosed with AAV (GPA or MPA subtype), who has not achieved remission (BVAS score of 0) for ≥ 3 months after receiving standardized treatment. Severe patients who have previously undergone standardized treatment to induce remission and are now relapsing after maintenance therapy; ②The patient is currently or has a positive ANCA during the course of the disease; ③Severe illness (severe organ involvement or life-threatening) requiring treatment (BVAS score ≥ 3.0); The definition of severe illness is vasculitis with life-threatening or organ manifestations.
for refractory LN
Exclusion Criteria:
-Subjects who meet any of the following criteria should be excluded from this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lymphocyte clearance before PRG-1801 cells' infusion; Plan to design two dose levels (2.5x10\^6 CAR-T/kg and 5.0x10\^6 CAR-T/kg), with 3-6 AAV and LN subjects included in each dose group, totaling 12-24 subjects. Within each dose group, the next subject can be administered after the previous subject has completed at least 14 days of safety observation. Dose group 1: with a dosage of 2.5x10\^6 (cells/kg) per dose Dose group 2: with a dosage of 5.0x10\^6 (cells/kg) per dose
Drug: PRG-1801 (CAR-T against BCMA)
Patients with refractory LN and ANCA-associated vasculitis will be treated with PRG-1801
AE Incidence of PRG-1801 Single Infusion
AE Incidence of PRG-1801 Single Infusion
Time frame: 24 months after PRG-1801 infusion
Types and incidence of dose-limiting toxicity(DLT) after PRG-1801 cells infusion in subjects with refractory ANCA-associated vasculitis and refractory LN.
To evaluate the DLT occurred within 28 days and 3 months after PRG-1801 infusion
Time frame: 28 days and 3 months after PRG-1801 infusion
Therapeutic effects-For refractory ANCA-associated vasculitis(The proportion of subjects who maintained remission after cell infusion)
The proportion of subjects who maintained remission after cell infusion
Time frame: Month1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18, Month 24 after cell infusion
Therapeutic effects-For refractory ANCA-associated vasculitis(Changes in VDI (Vasculitis Damage Index) scores from baseline after cell infusion)
Changes in VDI (Vasculitis Damage Index) scores from baseline after cell infusion
Time frame: Month1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18, Month 24 after cell infusion
Therapeutic effects-For refractory ANCA-associated vasculitis (Changes in glomerular filtration rate compared to baseline after cell infusion in subjects with renal involvement.)
Changes in glomerular filtration rate compared to baseline after cell infusion in subjects with renal involvement.
Time frame: Month1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18, Month 24 after cell infusion
Therapeutic effects-For refractory LN (Changes in SLEDAI-2000 score from baseline after cell infusion)
Changes in SLEDAI-2000 score from baseline after cell infusion
Time frame: Month1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18, Month 24 after cell infusion
Therapeutic effects-For refractory LN (Changes in FACIT fatigue score from baseline after cell infusion )
Changes in FACIT fatigue score from baseline after cell infusion
Time frame: Month1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18, Month 24 after cell infusion
Therapeutic effects-For refractory LN (Changes in PGA score (0-10) from baseline after cell infusion)
Changes in PGA score (0-10) from baseline after cell infusion
Time frame: Month1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18, Month 24 after cell infusion
Therapeutic effects-For refractory LN (Changes in eGFR(mL/min/1.73 m2) relative to baseline after cell infusion)
Changes in eGFR(mL/min/1.73 m2) relative to baseline after cell infusion
Time frame: Month1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18, Month 24 after cell infusion
Therapeutic effects-For refractory LN (Changes in UPCR (g/24h)relative to baseline after cell infusion)
Changes in UPCR (g/24h)relative to baseline after cell infusion
Time frame: Month1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18, Month 24 after cell infusion
Therapeutic effects-For refractory LN (The proportion of subjects who achieved overall response rate after cell infusion.)
The proportion of subjects who achieved overall response rate after cell infusion.
Time frame: Month1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18, Month 24 after cell infusion
Therapeutic effects-For refractory LN(The proportion of subjects who achieved complete renal response after cell infusion.)
The proportion of subjects who achieved complete renal response after cell infusion.
Time frame: Month1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18, Month 24 after cell infusion
PK feature evaluation (PK parameters related to CAR copy number)
PK parameters related to CAR copy number
Time frame: baseline, Day2, Day6, Day10, Day21, Day28, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18, Month 24 after cell infusion
Serum sBCMA level
Serum sBCMA level (count/uL)
Time frame: baseline, Day14, Day28, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18, Month 24 month after cell infusion
Serum ANCA titer level (AAV)
Serum ANCA titer level (AAV)
Time frame: baseline, Day14, Day28, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18, Month 24 month after cell infusion
Serum dsDNA level (LN)
Serum dsDNA level (IU/mL)
Time frame: baseline, Day14, Day28, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18, Month 24 month after cell infusion
Serum ANA titer level (LN)
Serum ANA titer level (IU/mL)
Time frame: baseline, Day14, Day28, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18, Month 24 month after cell infusion
Serum complement C3 levels
Serum complement C3 levels (g/L)
Time frame: baseline, Day14, Day28, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18, Month 24 month after cell infusion
Serum complement C4 levels
Serum complement C4 levels (g/L)
Time frame: baseline, Day14, Day28, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18, Month 24 month after cell infusion
Serum immunoglobulin quantification
Serum immunoglobulin quantification (g/L)
Time frame: baseline, Day14, Day28, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18, Month 24 month after cell infusion
Levels of CRP levels
Levels of CRP levels (mg/L)
Time frame: baseline, Day2, Day6, Day10, Day14, Day21, Day28 after cell infusion
Levels of ferritin levels
Levels of ferritin levels (ug/L)
Time frame: baseline, Day2, Day6, Day10, Day14, Day21, Day28 after cell infusion
Levels of cytokine levels
Levels of cytokine levels (pg/mL)
Time frame: baseline, Day2, Day6, Day10, Day14, Day21, Day28 after cell infusion
Changes of peripheral blood lymphocyte subsets
Changes of peripheral blood lymphocyte subsets (count/uL)
Time frame: baseline, Day2, Day6, Day10, Day14, Day21, Day28, Month 2, Month 3, Month 6 after cell infusion
Expression levels of BCMA on peripheral blood B cell subsets surface
Expression levels of BCMA on peripheral blood B cell subsets surface (%), using flow cytometer method.
Time frame: baseline, through study completion, an average of 2 years
The level of anti drug antibody (ADA)
The level of anti drug antibody (ADA)
Time frame: baseline, through study completion, an average of 2 years
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2024 (actual). Primary completion is estimated for Feb 2026, 23 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PRG-1801
Lingli Dong